The company will partner with its global biologics research and development arm MedImmune to carry out the genomics initiative, along with collaborators Human Longevity of the U.S, the Wellcome Trust Sanger Institute of the U.K. and The Institute for Molecular Medicine of Finland.
“Using the power of genomics is the foundation of our ambition to develop the most innovative and impactful treatments for patients,” said Menelas Pangalos, executive vice president of innovative medicines and early development at AstraZeneca. “With the advent of next generation sequencing and the increased sophistication of data analysis, the time is now right to immerse ourselves fully in the international genomics community through these pioneering collaborations and through the creation of our own genome center.”
More articles on genomics:
Intermountain, Stanford establish research program focused on precision health: 6 things to know
Physicians offer patients little insight on their genomic testing results
9 questions about precision medicine, answered
